Earnings Call
May 5, 2026
Q1 FY2026
EPS Estimate
3.41
EPS Actual
3.47
Post-Earnings Close
$562.97
Earnings Reaction
-0.0%
IDEXX Laboratories opened 2026 with one of its strongest quarterly performances in recent memory, posting organic revenue growth of 11% and EPS of $3.47, a 15% comparable increase that cleared consensus estimates. The headline numbers, however, only partially capture what was a quarter of broad-based execution: CAG Diagnostics recurring revenues grew 11% organically, VetLab consumables surged 15%, Reference Lab volumes accelerated, and the software and imaging segment set an all-time record for diagnostic imaging placements. Gross margins expanded roughly 90 basis points on a comparable basis, and free cash flow conversion on a trailing twelve-month basis reached 99%. Management raised full-year revenue guidance by $42 million at the midpoint and lifted EPS guidance by $0.13 per share net of a $0.05 equity investment loss, signaling genuine confidence rather than a mechanical beat-and-raise.
Report generated on May 6, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full IDXX analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.